Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business
Boston Scientific has invested heavily in Georgia-based MiRus, a rising name in the competitive TAVR landscape.
FDA clears next-gen contrast management system for the cath lab
The Acist Pro Diagnostic System provides real-time contrast tracking, customizable presets and on-screen troubleshooting.
Cardiologists are first in world to use new leaflet-splitting technique during TAVR
Performing TAVR on a patient with bicuspid AS can be challenging. Transcatheter aortic root tricuspidization may represent a new treatment strategy for these patients, according to a new first-in-human trial.
J&J launches Shockwave Medical’s next-generation coronary IVL catheter
The Shockwave C2 Aero Coronary IVL Catheter is based on years of user feedback. For example, it was built with improved deliverability and repositioning capabilities in mind.
Routine testing is needed to locate patients who may not benefit from clopidogrel
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Medtronic’s RDN system receives new reimbursement approval

More than 40 million adults now have improved access to Medtronic's Symplicity Spyral renal denervation technology.

After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

PAD patients could be missing out on recommended care following major lower extremity amputations

Patients undergoing the procedures due to infection, chronic limb-threatening ischemia and other serious complications may not be receiving the follow-up care their need.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

$iad Ali, MD, DPhil, director of the DeMatteis Cardiovascular Institute and director investigational interventional cardiology, St. Francis Hospital and Heart Center, explains how coronary computed tomography angiography (CCTA) offers a shift in cardiac care and interventional cardiology because of the information it offers on plaque burden and ischemia based on fractional flow reserve CT (FFR-CT). #TCT #YesCCT$

CCTA becoming an essential tool for interventional cardiologists

Ziad Ali, MD, explains how coronary computed tomography angiography is creating a major shift in cardiac care.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

iron bioresorbable scaffold Biotyx Medical

Ultrathin iron bioresorbable scaffold shows promise in first randomized trial

An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.

New heart catheter for cell therapy delivery 1 step closer to FDA approval

The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue.

Interventional Cardiology

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business

FDA clears next-gen contrast management system for the cath lab

Cardiologists are first in world to use new leaflet-splitting technique during TAVR

J&J launches Shockwave Medical’s next-generation coronary IVL catheter

Routine testing is needed to locate patients who may not benefit from clopidogrel